TROP2‐guided aggregation‐induced emission‐luminogen nanoparticles overcome sacituzumab govitecan resistance via mitochondrial oxidative stress and immunogenic cell death in triple‐negative breast cancer

Documenti analoghi

• TROP2‐guided AIE‐luminogen nanoparticles overcome sacituzumab govitecan resistance via mitochondrial oxidative stress and immunogenic cell death in triple‐negative breast cancer (6/2025)
  di: Nisha Wu, et al.
  Pubblicazione: (2025)
• Anti‐TIF1‐γ‐associated dermatomyositis associated with recurrent metastatic triple‐negative breast cancer: Dramatic clinical response to sacituzumab govitecan
  di: Wei‐Yao Wang, et al.
  Pubblicazione: (2024)
• Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group
  di: Salih Tunbekici, et al.
  Pubblicazione: (2025)
• Charged aggregation‐induced emission luminogens for bioimaging and phototherapy
  di: Junjie Feng, et al.
  Pubblicazione: (2024)
• Development and verification of a novel immunogenic cell death‐related signature for predicting the prognosis and immune infiltration in triple‐negative breast cancer
  di: Jiachen Li, et al.
  Pubblicazione: (2024)